Moreover, monitoring AXL expression in cancer patients will allow oncologists to identify which patient subgroups would benefit most from AXL-targeted therapies and could pave the way for a more personalized and effective treatment strategy for, among others, AML patients. The gene discussed is AXL; the disease is acute myeloid leukemia.